Changes in Mifepristone Use at Pharmacies After Removal of the FDA In-Person Dispensing Requirement
This cross-sectional study examines access to mifepristone through retail and mail-order pharmacies following the US Food and Drug Administration’s (FDA) removal of its in-person dispensing requirement.
Authors
- Christopher A. Scannell (ORCID: https://orcid.org/0000-0002-5944-4461)
- Rebecca Myerson (ORCID: https://orcid.org/0000-0001-7567-936X)
- Pragya Kakani
- Dima Mazen Qato
Institutions
- University of Southern California (US)
- Emory University (US)
- Cornell University (US)
Publication Details
- Journal
- JAMA
- Published
- 2026-04-13
- DOI
- https://doi.org/10.1001/jama.2026.3419
- Primary Topic
- Pharmaceutical Quality and Counterfeiting
- Type
- article
- Field-Weighted Citation Impact
- 0.00